Clinical Cancer Research, Vol 1, Issue 8 913-920, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis

DL Uhlman, P Nguyen, JC Manivel, G Zhang, K Hagen, E Fraley, D Aeppli and GA Niehans
Departments of Medicine, Laboratory Medicine and Pathology, Urologic Surgery, and Biostatistics, University of Minnesota, Minneapolis, Minnesota 55455, USA.

Papillary renal carcinomas are a cytogenetically unique subset of renal carcinomas that have been reported to be clinically less aggressive. We have examined 19 papillary tumors for immunohistochemical expression of the epidermal growth factor receptor (EGF-R) and its ligand, transforming growth factor alpha (TGF-alpha). EGF-R and TGF-alpha expression was also studied in 149 nonpapillary tumors and 7 mixed papillary/solid tumors. EGF-R and TGF-alpha expression were compared to histology, stage, metastatic behavior, and survival. Formalin-fixed, paraffin-embedded nephrectomy specimens collected between 1977 and 1986 were stained with antibodies to EGF-R and TGF-alpha. Patients with papillary tumors were found to present with earlier stage disease and had significantly longer survival. Papillary tumors had a significantly lower rate of EGF-R positivity than solid pattern tumors (21% versus 73%, P < 0.001). Intermediate or strong cell membrane immunoreactivity for EGF-R was associated with high tumor grade and poor disease-specific survival. EGF-R positivity in the primary tumor was associated with the presence of metastatic disease and with metastatic spread to lung versus bone. Tumor parenchymal TGF-alpha staining was present in 50% of the cases and was not associated with stage or grade. Unrelated to tumor parenchymal TGF staining, tumor vessels stained for TGF-alpha in 56% of the cases. Vessel TGF-alpha staining was absent in papillary tumors (P < 0.001). The improved clinical behavior of papillary tumors as compared to nonpapillary renal tumors may be related, in part, to their relatively lower levels of EGF-R expression.

This article has been cited by other articles:

				T. Sasaki, T. Nakamura, R. B. Rebhun, H. Cheng, K. S. Hale, R. Z. Tsan, I. J. Fidler, and R. R. Langley Modification of the Primary Tumor Microenvironment by Transforming Growth Factor {alpha}-Epidermal Growth Factor Receptor Signaling Promotes Metastasis in an Orthotopic Colon Cancer Model Am. J. Pathol., July 1, 2008; 173(1): 205 - 216. [Abstract] [Full Text] [PDF]

				T. Kuwai, T. Nakamura, S.-J. Kim, T. Sasaki, Y. Kitadai, R. R. Langley, D. Fan, S. R. Hamilton, and I. J. Fidler Intratumoral Heterogeneity for Expression of Tyrosine Kinase Growth Factor Receptors in Human Colon Cancer Surgical Specimens and Orthotopic Tumors Am. J. Pathol., February 1, 2008; 172(2): 358 - 366. [Abstract] [Full Text] [PDF]

				J. Lechner, N. A. Malloth, P. Jennings, D. Heckl, W. Pfaller, and T. Seppi Opposing roles of EGF in IFN-{alpha}-induced epithelial barrier destabilization and tissue repair Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1843 - C1850. [Abstract] [Full Text] [PDF]

				L. J. Costa and H. A. Drabkin Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies Oncologist, December 1, 2007; 12(12): 1404 - 1415. [Abstract] [Full Text] [PDF]

				W. Wu, M. S. O'Reilly, R. R. Langley, R. Z. Tsan, C. H. Baker, N. Bekele, X. M. Tang, A. Onn, I. J. Fidler, and R. S. Herbst Expression of epidermal growth factor (EGF)/transforming growth factor-{alpha} by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice Mol. Cancer Ther., October 1, 2007; 6(10): 2652 - 2663. [Abstract] [Full Text] [PDF]

				F. Lin, P. L. Zhang, X. J. Yang, J. W. Prichard, M. Lun, and R. E. Brown Morphoproteomic and Molecular Concomitants of an Overexpressed and Activated mTOR Pathway in Renal Cell Carcinomas Ann. Clin. Lab. Sci., January 1, 2006; 36(3): 283 - 293. [Abstract] [Full Text] [PDF]

				C Langner, M Ratschek, P Rehak, L Schips, and R Zigeuner Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation? J. Clin. Pathol., July 1, 2004; 57(7): 773 - 775. [Abstract] [Full Text] [PDF]

				M. Sumitomo, T. Asano, J. Asakuma, T. Asano, A. Horiguchi, and M. Hayakawa ZD1839 Modulates Paclitaxel Response in Renal Cancer by Blocking Paclitaxel-Induced Activation of the Epidermal Growth Factor Receptor-Extracellular Signal-Regulated Kinase Pathway Clin. Cancer Res., January 15, 2004; 10(2): 794 - 801. [Abstract] [Full Text] [PDF]

				N. B. Haas, M. Smith, N. Lewis, L. Littman, G. Yeslow, I. D. Joshi, A. Murgo, J. Bradley, R. Gordon, H. Wang, et al. Weekly Bryostatin-1 in Metastatic Renal Cell Carcinoma: A Phase II Study Clin. Cancer Res., January 1, 2003; 9(1): 109 - 114. [Abstract] [Full Text] [PDF]

				P. D. Ryan and B. A. Chabner On Receptor Inhibitors and Chemotherapy Clin. Cancer Res., December 1, 2000; 6(12): 4607 - 4609. [Full Text]

				F. TERZI, M. BURTIN, and G. FRIEDLANDER Using Transgenic Mice to Analyze the Mechanisms of Progression of Chronic Renal Failure J. Am. Soc. Nephrol., November 1, 2000; 11(90002): 144S - 148. [Abstract] [Full Text]

				H. Bissig, J. Richter, R. Desper, V. Meier, P. Schraml, A. A. Schaffer, G. Sauter, M. J. Mihatsch, and H. Moch Evaluation of the Clonal Relationship between Primary and Metastatic Renal Cell Carcinoma by Comparative Genomic Hybridization Am. J. Pathol., July 1, 1999; 155(1): 267 - 274. [Abstract] [Full Text] [PDF]

				H. Moch, P. Schraml, L. Bubendorf, M. Mirlacher, J. Kononen, T. Gasser, M. J. Mihatsch, O. P. Kallioniemi, and G. Sauter High-Throughput Tissue Microarray Analysis to Evaluate Genes Uncovered by cDNA Microarray Screening in Renal Cell Carcinoma Am. J. Pathol., April 1, 1999; 154(4): 981 - 986. [Abstract] [Full Text] [PDF]

				R. J. Motzer, N. H. Bander, and D. M. Nanus Renal-Cell Carcinoma N. Engl. J. Med., September 19, 1996; 335(12): 865 - 875. [Full Text] [PDF]

				K. Datta, R. Nambudripad, S. Pal, M. Zhou, H. T. Cohen, and D. Mukhopadhyay Inhibition of Insulin-like Growth Factor-I-mediated Cell Signaling by the von Hippel-Lindau Gene Product in Renal Cancer J. Biol. Chem., June 30, 2000; 275(27): 20700 - 20706. [Abstract] [Full Text] [PDF]

				J. M. Boer, W. K. Huber, H. Sultmann, F. Wilmer, A. von Heydebreck, S. Haas, B. Korn, B. Gunawan, A. Vente, L. Fuzesi, et al. Identification and Classification of Differentially Expressed Genes in Renal Cell Carcinoma by Expression Profiling on a Global Human 31,500-Element cDNA Array Genome Res., November 1, 2001; 11(11): 1861 - 1870. [Abstract] [Full Text] [PDF]